DE
About us
Company
Strategy & Mission
Management
Career
Portfolio
Pipeline
Budesolv
Tacrosolv
Satiasolv
Scientific Publications
Partnering
Business Development
Solv4U
Investors & ESG
Investment Highlights
Share information
Ad-hoc News
Financial publications
Facts & Figures
Financial Calendar
Responsibility & ESG
Annual General Meeting
Capital Transactions
IR contact
News & Publications
Corporate News
Scientific Publications
Events & Press
Downloads
DE
Financial publications
Marinomed Biotech AG
Investors & ESG
Financial publications
Financial reports
Investor presentations
Conference Calls
Financial reports
ALL
2025
2024
2023
2022
2021
2020
2019
2018
2017
Annual Report 2024
(3 MB)
Annual Financial Report 2024
(5 MB)
Sustainability Report 2024 (excerpt from Annual Report 2024)
(3 MB)
Half-Year Financial Report 2024
(2 MB)
Bericht des Vorstands der Marinomed Biotech AG (FN 276819 m), ISIN ATMARINOMED6 gemäß §§ 174 Abs. 4 iVm 153 Abs. 4 AktG (Ausschluss des Bezugsrechts bei Ausgabe von Wandelschuldverschreibungen) (German only)
(94 KB)
Bericht des Vorstands der Marinomed Biotech AG (FN 276819 m), ISIN ATMARINOMED6 gemäß §§ 171 Abs. 1 iVm 153 Abs. 4 AktG (Ausschluss des Bezugsrechts bei Kapitalerhöhung aus genehmigtem Kapital) (German only)
(128 KB)
Update Q1 2024
(2 MB)
Annual Report 2023
(7 MB)
Sustainability Report 2023 (excerpt from Annual Report 2023)
(4 MB)
Annual Financial Report 2023
(4 MB)
Jahresfinanzbericht 2023 (ESEF)
(1 MB)
Update Q3 2023
(1 MB)
Half-Year Financial Report 2023
(2 MB)
Update Q1 2023
(2 MB)
Annual Report 2022
(8 MB)
Sustainability Report 2022 (excerpt from Annual Report 2022)
(4 MB)
Annual Financial Report 2022
(4 MB)
Jahresfinanzbericht 2022 (ESEF)
(1 MB)
Update Q3 2022
(2 MB)
Half-Year Financial Report 2022
(4 MB)
Update Q1 2022
(2 MB)
Annual Report 2021
(2 MB)
Sustainability Report 2021 (excerpt from Annual Report 2021)
(944 KB)
Financial Report 2021
(2 MB)
Jahresfinanzbericht 2021 (ESEF)
(1 MB)
Update Q3 2021
(176 KB)
Half-Year Financial Report 2021
(385 KB)
Update Q1 2021
(168 KB)
Bericht des Vorstands der Marinomed Biotech AG FN 276819 m, ISIN ATMARINOMED6 gemäß § 174 Abs 4 iVm § 153 Abs 4, § 171 Abs 1 AktG (German Only)
(106 KB)
Annual Report 2020
(938 KB)
Financial Report 2020
(837 KB)
Jahresfinanzbericht 2020 (ESEF)
(248 KB)
Update Q3 2020
(178 KB)
Half-Year Financial Report 2020
(329 KB)
Update Q1 2020
(141 KB)
Veröffentlichung gemäß § 5 Abs. 2 Rechnungslegungs-Kontrollgesetz (RL-KG) vom 04.09.2020 (German only)
(25 KB)
Financial Report 2019
(2 MB)
Annual Report 2019
(1 MB)
Update Q3 2019
(678 KB)
Half-Year Financial Report 2019 incl. UGB
(1 MB)
Half-Year Financial Report 2019
(845 KB)
Update Q1 2019
(690 KB)
Financial Report 2018
(2 MB)
Annual Report 2018
(3 MB)
Annual Report 2017
(2 MB)
Audit report (German only)
(2 MB)
Investor presentations
ALL
2024
2023
2022
2021
2020
2019
2018
Investor Presentation Deutsches Eigenkapitalforum 2024
(822 KB)
Investor Presentation Q1 2024
(961 KB)
Investor Presentation Equity Forum Spring Conference
(1 MB)
Investor Presentation Full Year 2023
(1 MB)
Investor Presentation: Marinomed Biotech Roundtable at AlsterResearch Online Healthcare Conference
(1 MB)
Investor Presentation: Carragelose Business Strategic Options (18.12.2023)
(818 KB)
Investor Presentation Q3 2023
(2 MB)
Investor Presentation The Finest CEElection Investor Conference
(1 MB)
Investor Presentation Dr. Kalliwoda Roadshow Spain 2023
(1 MB)
Investor Presentation Hamburger Investorentage 2023
(1 MB)
Investor Presentation Equity Forum September 2023
(1 MB)
Investor Presentation H1 2023
(2 MB)
Investor Presentation Q1 2023
(1 MB)
Investor Presentation Equity Forum Frankfurt May 2023
(2 MB)
Investor Presentation Full Year 2022
(1 MB)
Investor Presentation RBI Conference Zürs April 2023
(2 MB)
Investor Presentation Roadshow London March 2023
(2 MB)
Investor Presentation Full Year 2022
(1 MB)
Investor Presentation Q3 2022
(2 MB)
Investor Presentation H1 2022
(2 MB)
Investor Presentation Q1 2022
(1 MB)
Investor Presentation LSX Inv€$tival November 2022
(2 MB)
Investor Presentation Equity Forum 2022
(2 MB)
Investor Presentation - Full Year Results 2021
(4 MB)
Investor Presentation Q3 2021
(2 MB)
Investor Presentation H1 2021
(960 KB)
Investor Presentation Q1 2021
(1 MB)
Investor Presentation - Results FY 2020
(1 MB)
Investor Presentation Q3 2020
(584 KB)
Investor Presentation SARS-CoV-2
(345 KB)
Investor Presentation H1 2020
(918 KB)
Investor Presentation Q1 2020
(574 KB)
Investor Presentation - Results FY 2019
(965 KB)
Investor Presentation Q3 2019
(676 KB)
Investor Presentation H1 2019
(999 KB)
Investors Update 2018
(832 KB)
Conference calls
ALL
2024
2023
2022
2021
2020
Conference Call Invitation - Results Q1 2024
(48 KB)
Conference Call Invitation - Full Year Results 2023
(49 KB)
Conference Call Invitation - Results Q3 2023
(49 KB)
Conference Call Invitation - Half Year Results 2023
(49 KB)
Conference Call Invitation - Results Q1 2023
(51 KB)
Conference Call Invitation - Full Year Results 2022
(49 KB)
Conference Call Invitation - Results Q3 2022
(47 KB)
Conference Call Invitation - Half Year Results 2022
(70 KB)
Conference Call Invitation - Results Q1 2022
(67 KB)
Conference Call Invitation - Full Year Results 2021
(140 KB)
Conference Call Invitation - Results Q3 2021
(138 KB)
Conference Call Invitation - Half-Year Results 2021
(127 KB)
Conference Call Invitation - Results Q1 2021
(47 KB)
Conference Call Invitation - Full Year Results 2020
(132 KB)
Conference Call Invitation - Results Q3 2020
(61 KB)
Conference Call Invitation - Results H1 2020
(61 KB)
Conference Call Invitation - Results Q1 2020
(59 KB)
Tobias Meister
Investor Relations
ir@marinomed.com
Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg, Austria
+43 2262 90300
office@marinomed.com
